Jamal Rahaman, MD
img_Jamal Rahaman
CLINICAL PROFESSOR | Obstetrics, Gynecology and Reproductive Science
Are you a patient?
Specialties
Obstetrics and Gynecology, Gynecologic Oncology
Research Topics
Angiogenesis, Anti-Tumor Therapy, Cancer, Cancer Genetics, Clinical Genomics, Gene Expressions, Gene Regulation, Genomics, Metastasis, Molecular Biology, Oncogenes, Personalized Medicine, Positron Emission Tomography, Robotic Surgery, Translational Research, Tumor Suppressor Genes, Tumorigenesis
Multi-Disciplinary Training Area
Cancer Biology [CAB]

Active Clinical Trials

GOG0218
A Phase III Trial of Carboplatin and Paclitaxel plus placebo versus Carboplatin and Paclitaxel plus concurrent Bevacizumab (NSC # 704865, IND #7921) followed by placebo, versus Carboplatin and Paclitaxel plus concurrent and extended Bevacizumab, in women who are newly diagnosed, previously untreated, Stage III or IV, epithelial overian or primary peritoneal cancer NCI-supplied agent(s): Bevacizumab/Placebo (NSC #704865, IND #7921)

GOG0213 A Phase III randomized controlled clinical trial of Carboplatin and Paclitazel alone or in combination with Bevacizumab (NSC #704865, IND #7921) followed by Bevacizumab and secondary cytoreductive surgery in platinum-sensitive, recurrent ovarian, peritone primary and fallopian tube cancer.  NCI-supplied agents: Bevacizumab (NSC #704865, IND #7921)

GOG0212
A randomized phase III trial of maintenance chemotherapy comparing 12, monthly cycles of single agent Paclitaxel or CT-2103 (IND #70177), versus no treatment until documented relapse in women with advanced ovarian or primary peritoneal cancer achieve a complete clinical response to primary platinum/taxane chemotherapy

GOG0209
A Randomized Phase III Trial of Doxorubicin/Cisplatin/Paclitaxel and G-CSF versus Carboplatin/Paclitaxel in Patients with Stage III & IV or Recurrent Endometrial Cancer

GOG0210
A Molecular Staging Study of Endometrial Carcinoma

GOG0233 / ACRIN 6671
Utility of preoperative FDG-PET/CT and Ferumoxtran-10 MRI scanning prior to primary chemoradiation therapy to detect retroperitoneal lymph node metastasis in patients with locoregionally advanced (IB2, IIA ≥4 CM, IIB-IVA) carcinoma of the cervix

GOG0215
A Phase II Randomized Study of the Effect of Zoledronic Acid versus Observation on Bone Mineral Density of the Lumbar Spine in Women who Elect to Undergo Risk-Reducing Surgery that Results in Removal of Both Ovaries

GOG0136
Acquisition of human gynecologic specimens and serum to be used in studying the causes, diagnosis, prevention and treatment of cancer

GCO# 06-0832
Investigator Initiated Phase I/II trial of combination intra-peritoneal Docetaxel and intravenous pegylated liposomal doxorubicin in persistent epithelial ovarian, peritoneal and fallopian tube carcinoma.

GCO # 04-0754
A Phase lll, Double-Blind, Randomized, Controlled, Multi-Center, Study to Evaluate the Efficacy of GlaxoSmithKline Biologicals ' HPV-16/18 VLP/AS04 Vaccine Compared to Hepatitis A Vaccine as Control in Prevention of Persistent HPV-16 or HPV-18 Cervical Infection and Cervical Neoplasia, Administered Intramuscularly According to a 0, 1, 6 Month Schedule in Healthy Females 15-25 Years of Age
Protocol 580299/008

GCO # 07-0267
A Phase lllb, Observer-Blind, Randomized, Multicenter Study With Two Parallel Groups to Compare the Immunogenicity of GlaxoSmithKline Biological 's HPV-16/18 L 1/AS04 Vaccine Versus Merck 's Gardasil Vaccine When Administered Intramuscularly According to a 3-Dose Schedule in Healthy Adult Females 18-45 Years of Age
Protocol 108933 (HPV-010)

Translational Research

  • KLF6 is a novel regulator of VEGF in Ovarian cancer cell lines.
  • Utility of a novel microarray assessment of critical signaling pathways in ovarian cancer
  • MicroRNA signatures in Human Ovarian cancer and response to chemotherapy.
  • Comparative Genomic Hypridiztion (CGH) Predicts Time to Recurrence in Primary Ovarian Carcinoma.
  • Combination anti-estrogen and proteosome inhibitor biologic therapy for uterine cancer.

MD, University of the West Indies-Jamaica

Residency, Obstetrics & Gynecology, Mount Hope Maternity Hospital

Residency, Obstetrics & Gynecology, Lincoln Medical & Mental Health Center

Residency, Obstetrics & Gynecology, Mount Sinai Hospital

Fellowship, Thoracic Surgery (Cardiothoracic Vascular Surgery), Texas Heart Hospital

Fellowship, Gynecologic Oncology, Mount Sinai Hospital

Certifications

American Board of Obstetrics and Gynecology

2010

Sydney Druce Award

Department of Obstetrics & Gynecology at Mount Sinai

2008

Best Doctors in New York

New York Magazine

2008

Marquis-Who's Who in America

2007

Biltmore Who's Who

2007

Top Doctor

US News & World Report

2007

Super Doctor

New York Times

2002

Top Doctors in New York Metro Area

Castle Conolly Medical

2002

1st Place

ACOG Annual Meeting Film Festival

2002

Top Minimal Invasive Surgeons

New York Magazine

2001

CREOG/ACOG National Faculty Teaching Award for Residency Education

1990

Resident of the Year Award

Lincoln Medical Center

1984

Class Prize in Internal Medicine

1984

Leonard de Cordova Medal in Physiology

1984

Noel Haye Prize in Anatomy

1979

University of the West Indies Open Scholarship

1979

Trinidad and Tobago National Scholarship

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Dr. Rahaman has not yet completed reporting of Industry relationships.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.